LONDON, Oct. 24, 2017 /PRNewswire/ -- Anaplastic Thyroid Cancer clinical trials report from VPA Research provides comprehensive analysis and trends in global Anaplastic Thyroid Cancer disease clinical trials. The research work analyzes the evolution of Anaplastic Thyroid Cancer clinical trial trends across countries and regions.Download the full report: https://www.reportbuyer.com/product/5158749The report focuses on drugs and therapies being evaluated for Anaplastic Thyroid Cancer treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Anaplastic Thyroid Cancer clinical trials.Major drugs under development in Anaplastic Thyroid Cancer are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.Scope of the Report-- Number of Anaplastic Thyroid Cancer clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas- Trial information by Phase and Subjects recruited- Trial information by status, type, sponsor type- Drugs used for treatment of Anaplastic Thyroid Cancer- Both observational and interventional trials analyzed- Success rates of trials are analyzed- Trends in enrollment over the past ten years identified- Leading sponsors of Anaplastic Thyroid Cancer clinical trials worldwide are listedReasons to Buy-- Track competition and design competitive advantages- Identify right partners to associate with for further research- Evaluate potential opportunities available in further clinical trials of the disease- Formulate business development strategies through success rates of clinical trials- Identify quick markets for recruiting subjects based on trials count by each marketExecutive SummaryAnaplastic thyroid cancer (ATC), also termed undifferentiated thyroid cancer or high grade carcinoma, is a rare form of thyroid cancers. ATC accounts for around 2% to 5% of total thyroid cancers. The rare type of thyroid cancers is not much common and initiates from follicular cells of thyroid gland. It typically originates from inside the gland and rapidly expands out of the tissue. This aggressive metastasis results in poor prognosis, resulting in low survival rates. Typical ages affected due to ATC are in older people aged over 60.The cancer type occurs in advanced stages including-- Stage IVA- cancer cells contained within thyroid gland- Stage IVB- outside the gland to distant locations- Stage IVC- outside the gland to much farther distancesDrugs in Clinical Trials of Anaplastic Thyroid Cancer-AdalimumabAtezolizumabBevacizumabcarboplatinCeritinibCisplatinCobimetinibCrolibulindabrafenibDocetaxeldoxorubicin hydrochloridedurvalumabefatutazoneEverolimusFosbretabulinIpilimumabLenvatinibNivolumabPaclitaxelPembrolizumabSapanisertibSorafenibTrametinibtremelimumabvemurafenibDownload the full report: https://www.reportbuyer.com/product/5158749
About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com
For more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected]
Tel: +44 208 816 85 48 Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/anaplastic-thyroid-cancer-drug-profiles-and-clinical-trials--global-trends-and-analysis-review-h2-2017-300542385.html
SOURCE ReportBuyer
